X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (395) 395
male (227) 227
cardiac & cardiovascular systems (220) 220
female (211) 211
middle aged (195) 195
aged (170) 170
index medicus (142) 142
risk factors (90) 90
treatment outcome (86) 86
aspirin (83) 83
myocardial infarction - drug therapy (79) 79
atrial fibrillation (67) 67
adult (66) 66
anticoagulants (64) 64
medicine, general & internal (62) 62
platelet aggregation inhibitors - therapeutic use (61) 61
stroke (60) 60
anticoagulants - therapeutic use (58) 58
cardiology (58) 58
therapy (58) 58
heart attacks (57) 57
myocardial infarction (57) 57
abridged index medicus (55) 55
time factors (52) 52
aspirin - therapeutic use (51) 51
mortality (51) 51
risk (50) 50
peripheral vascular disease (49) 49
drug therapy, combination (48) 48
acute coronary syndromes (47) 47
acute myocardial-infarction (47) 47
myocardial infarction - therapy (47) 47
cardiovascular disease (46) 46
follow-up studies (45) 45
prognosis (44) 44
warfarin (43) 43
clopidogrel (42) 42
fibrinolytic agents - therapeutic use (42) 42
myocardial-infarction (42) 42
percutaneous coronary intervention (42) 42
hematology (41) 41
prevention (40) 40
thrombolytic therapy (40) 40
bleeding (39) 39
electrocardiography (39) 39
care and treatment (38) 38
clinical trials as topic (37) 37
drug therapy (37) 37
coronary angiography (36) 36
hemorrhage - chemically induced (36) 36
prospective studies (36) 36
cardiovascular diseases (35) 35
heart attack (35) 35
medicine & public health (35) 35
angioplasty (34) 34
angioplasty, balloon, coronary (34) 34
double-blind method (34) 34
myocardial infarction - mortality (33) 33
thrombolysis (32) 32
aged, 80 and over (30) 30
anticoagulants - administration & dosage (30) 30
heart failure (30) 30
management (30) 30
medical and health sciences (30) 30
medicin och hälsovetenskap (30) 30
risk assessment (30) 30
anticoagulants - adverse effects (29) 29
patients (29) 29
antiplatelet therapy (28) 28
antithrombotic therapy (28) 28
atrial fibrillation - drug therapy (28) 28
clinical trials (28) 28
myocardial infarction - physiopathology (27) 27
randomized controlled trials as topic (27) 27
secondary prevention (27) 27
cardiac patients (26) 26
coronary heart disease (26) 26
myocardial infarction - prevention & control (26) 26
netherlands (26) 26
administration, oral (25) 25
atrial fibrillation - complications (25) 25
stroke - prevention & control (25) 25
aspirin - administration & dosage (24) 24
cardiovascular (24) 24
trial (24) 24
cardiac arrhythmia (23) 23
recurrence (23) 23
thrombosis (23) 23
ticlopidine - analogs & derivatives (23) 23
coronary vessels (22) 22
hemorrhage (22) 22
prevalence (22) 22
research (22) 22
heart (21) 21
myocardial infarction - diagnosis (21) 21
platelet aggregation inhibitors - adverse effects (21) 21
survival analysis (21) 21
aspirin - adverse effects (20) 20
ischemia (20) 20
low-dose aspirin (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (648) 648
Dutch (62) 62
Spanish (5) 5
Polish (2) 2
Portuguese (2) 2
Czech (1) 1
German (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Heart, ISSN 1355-6037, 02/2017, Volume 103, Issue 4, pp. 307 - 314
Journal Article
European Heart Journal, ISSN 0195-668X, 10/2016, Volume 37, Issue 38, pp. 2882 - 2889A
The relationship between outcomes and time after diagnosis for patients with non-valvular atrial fibrillation (NVAF) is poorly defined, especially beyond the... 
Stroke prevention | Stroke | Anticoagulation | Atrial fibrillation | Bleeding | MORTALITY | CARDIAC & CARDIOVASCULAR SYSTEMS | HEART-FAILURE | PREVENTION | DEATH | PREVALENCE | RISK STRATIFICATION SCHEMES | ANTITHROMBOTIC TREATMENT | RHYTHM MANAGEMENT | REGISTRY | Clinical Research
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2012, Volume 367, Issue 14, pp. 1297 - 1309
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article